


Connecting via Winsock to STN

Welcome to STN International! Enter x:x

FILE 'HOME' ENTERED AT 08:13:02 ON 28 JAN 2010

=> file reg

Uploading C:\Program Files\Stnexp\Queries\10593829\rce.str



chain nodes :
1 2 3 7 8 9 10 11 14 15 16 17 18 19 20 21 22 23 24 25 26
chain bonds :
1-2 1-24 2-7 3-24 7-8 7-9 9-10 10-11 10-25 14-15 14-26 15-16 15-17
15-18 18-19 19-20 20-21 20-22 21-23 25-26
exact/norm bonds :
2-7 3-24 7-8 10-11 10-25 14-15 15-16 15-17 15-18 18-19 20-22 21-23
exact bonds :
1-2 1-24 7-9 9-10 14-26 19-20 20-21 25-26

Match level :
1:CLASS 2:CLASS 3:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS 11:CLASS 14:CLASS
15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS 21:CLASS 22:CLASS
23:CLASS 24:CLASS 25:CLASS 26:CLASS

Generic attributes :

3:
Saturation : Saturated
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : Exactly 1
Type of Ring System : Monocyclic

Element Count :

Node 3: Limited

C,C5

O,O1

L10 STRUCTURE UPLOADED

=> s l10
SAMPLE SEARCH INITIATED 08:18:44 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 191 TO ITERATE

100.0% PROCESSED 191 ITERATIONS 4 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 2991 TO 4649
PROJECTED ANSWERS: 4 TO 200

L11 4 SEA SSS SAM L10

=> s l10 full

FULL SEARCH INITIATED 08:18:52 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 4207 TO ITERATE

100.0% PROCESSED 4207 ITERATIONS 34 ANSWERS
SEARCH TIME: 00.00.01

L12 34 SEA SSS FUL L10

=> file caplus

=> s l12
L13 2 L12

=> d l13 1-2 ibib abs hitstr
THE ESTIMATED COST FOR THIS REQUEST IS 11.62 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L13 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:1341454 CAPLUS
DOCUMENT NUMBER: 149:534508
TITLE: Preparation of carbohydrate-lipid analogs and their
use in preventing or treating viral infection
INVENTOR(S): Henry, Stephen Micheal
PATENT ASSIGNEE(S): Kode Biotech Ltd., N. Z.
SOURCE: PCT Int. Appl., 87pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2008133534	A2	20081106	WO 2008-NZ95	20080428
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,			

TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
 TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

AU 2008244737 A1 20081106 AU 2008-244737 20080428
 CA 2685269 A1 20081106 CA 2008-2685269 20080428

PRIORITY APPLN. INFO.:

NZ 2007-554853 A 20070427
 NZ 2007-556736 A 20070724
 NZ 2008-567754 A 20080424
 WO 2008-NZ95 W 20080428

OTHER SOURCE(S): MARPAT 149:534508

AB Carbohydrate-lipid analogs are prepared for their use as mimics of ligands for receptors expressed by a virus. In particular, the invention relates to the use of selected carbohydrate-lipid constructs in methods of inhibiting virus infection and/or promoting clearance of virus from infected subjects. Carbohydrate-lipid constructs selected for use in these methods where the virus is Human Immunodeficiency Virus (HIV) are provided.

IT **1075699-41-0P** **1075699-42-1P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of carbohydrate-lipid analogs and their use in preventing or treating viral infection)

RN 1075699-41-0 CAPLUS


CN 9-Octadecenoic acid (9Z)-, 1,1'-[(1R)-1-[17-[(O- α -D-galactopyranosyl-(1 \rightarrow 4)-O- β -D-galactopyranosyl-(1 \rightarrow 4)- β -D-glucopyranosyl)oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxo-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl] ester (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 1075699-42-1 CAPLUS
 CN 9-Octadecenoic acid (9Z)-, 1,1'-[(1R)-1-[16-[(O- α -D-galactopyranosyl-(1 \rightarrow 4)-O- β -D-galactopyranosyl-(1 \rightarrow 4)- β -D-glucopyranosyl)oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxo-7,14-diaza-3-phosphahexadec-1-yl]-1,2-ethanediyl] ester (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



L13 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2005:1042259 CAPLUS
 DOCUMENT NUMBER: 143:339681
 TITLE: Synthetic membrane anchors
 INVENTOR(S): Bovin, Nicolai; Gilliver, Lissa; Henry, Stephen;
 Korchagina, Elena
 PATENT ASSIGNEE(S): Kiwi Ingenuity Limited, N. Z.
 SOURCE: PCT Int. Appl., 109 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005090368	A1	20050929	WO 2005-NZ52	20050322
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2005223715	A1	20050929	AU 2005-223715	20050322
CA 2560781	A1	20050929	CA 2005-2560781	20050322
EP 1735323	A1	20061227	EP 2005-722123	20050322
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1938325	A	20070328	CN 2005-80009170	20050322
JP 2007530532	T	20071101	JP 2007-504907	20050322
IN 2006DN06089	A	20070831	IN 2006-DN6089	20061018
US 20070197466	A1	20070823	US 2007-593829	20070112

PRIORITY APPLN. INFO.:
 NZ 2004-531866 A 20040322
 NZ 2005-537941 A 20050128
 WO 2005-NZ52 W 20050322

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 143:339681

AB The invention relates to synthetic mols. such as modified glycolipids that spontaneously and stably incorporate into lipid by-layers, including cell membranes. Particularly, although not exclusively, the invention relates to the use of these mols. as synthetic membrane anchors or synthetic mol. constructs to effect qual. and quant. changes in the expression of cell surface antigens. Being able to effect qual. and/or quant. changes in the surface antigens expressed by a cell has diagnostic and therapeutic value. In a first aspect the invention consists in a mol. of the structure R-S2-L for use as a synthetic membrane anchor or in the preparation of synthetic mol. constructs where: R is a chemical reactive functional group such as bis(N-hydroxysuccinimidyl), bis(4-nitrophenyl), bis(pentafluorophenyl), and bis(pentachlorophenyl); S2 is a spacer linking R to L such as -CO(CH2)3CO-, -CO(CH2)4CO- (adipate (Ad)), and -CO(CH2)5CO-; and L is a lipid selected from the group consisting of diacyl- and dialkylglycerolipids, including glycerophospholipids, and sphingosine derived diacyl- and dialkylipids, including ceramide. In a second aspect, the invention consists in a synthetic mol. construct of the structure F-S1-S2-L where: F is an antigen selected from the group consisting of carbohydrates, proteins, lipids, lectins, avidins and biotin; S1-S2 is a spacer linking F to L; and L is a lipid selected from the group consisting of diacyl- and dialkylglycerolipids, including glycerophospholipids, and sphingosine derived diacyl- and dialkylipids, including ceramide.

IT	<u>865529-57-3P</u>	<u>865529-65-3P</u>	<u>865529-69-7P</u>
	<u>865529-73-3P</u>	<u>865529-77-7P</u>	<u>865529-81-3P</u>

RL: DGN (Diagnostic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(synthetic membrane anchors such as glycolipids that incorporate into bilayer membranes to modify expression of cell surface antigens in relation to diagnostic and therapeutic uses)

RN 865529-57-3 CAPLUS


CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[O-2-(acetylamino)-2-deoxy- α -D-galactopyranosyl-(1 \rightarrow 3)-O-[6-deoxy- α -L-galactopyranosyl-(1 \rightarrow 2)]- β -D-galactopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxo-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 865529-65-3 CAPLUS
CN Octadecanoic acid, (1R)-1-[17-[[O-2-(acetylamino)-2-deoxy- α -D-galactopyranosyl-(1 \rightarrow 3)-O-[6-deoxy- α -L-galactopyranosyl-(1 \rightarrow 2)]- β -D-galactopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxo-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 865529-69-7 CAPLUS


CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[O-6-deoxy- α -L-galactopyranosyl-(1 \rightarrow 2)-O-[α -D-galactopyranosyl-(1 \rightarrow 3)]- β -D-galactopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxo-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 865529-73-3 CAPLUS


CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[O-6-deoxy- α -L-galactopyranosyl-(1 \rightarrow 2)-O- β -D-galactopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxo-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 865529-77-7 CAPLUS


CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[2-O-(6-deoxy- α -L-galactopyranosyl)- β -D-galactopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxo-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B





RN 865529-81-3 CAPLUS

CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-(β -D-galactopyranosyloxy)-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxo-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





IT 865529-57-3D, salts 865529-58-4
865529-59-5 865529-60-8 865529-65-3D,
salts 865529-66-4 865529-67-5
865529-68-6 865529-69-7D, salts 865529-70-0
865529-71-1 865529-72-2 865529-73-3D,
salts 865529-74-4 865529-75-5
865529-76-6 865529-77-7D, salts 865529-78-8
865529-79-9 865529-80-2 865529-81-3D,
salts 865529-82-4 865529-83-5
865529-84-6 865529-85-7 865529-85-7D,
salts 865529-86-8 865529-87-9
865529-88-0 865529-89-1 865529-89-1D,
salts 865529-90-4 865529-91-5
865529-92-6

RL: DGN (Diagnostic use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(synthetic membrane anchors such as glycolipids that incorporate into bilayer membranes to modify expression of cell surface antigens in relation to diagnostic and therapeutic uses)


RN 865529-57-3 CAPLUS

CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[O-2-(acetylamino)-2-deoxy- α -D-galactopyranosyl-(1 \rightarrow 3)-O-[6-deoxy- α -L-galactopyranosyl-(1 \rightarrow 2)]- β -D-galactopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxo-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B





RN 865529-58-4 CAPLUS

CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[O-2-(acetylamino)-2-deoxy- α -D-galactopyranosyl-(1 \rightarrow 3)-O-[6-deoxy- α -L-galactopyranosyl-(1 \rightarrow 2)]- β -D-galactopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxo-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Double bond geometry as shown.



RN 865529-59-5 CAPLUS

CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[O-2-(acetylamino)-2-deoxy- α -D-galactopyranosyl-(1 \rightarrow 3)-O-[6-deoxy- α -L-galactopyranosyl-(1 \rightarrow 2)]- β -D-galactopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxo-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester, monopotassium salt (9CI) (CA INDEX NAME)



Absolute stereochemistry.
Double bond geometry as shown.



RN 865529-60-8 CAPLUS

CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[O-2-(acetylamino)-2-deoxy- α -D-galactopyranosyl-(1 \rightarrow 3)-O-[6-deoxy- α -L-galactopyranosyl-(1 \rightarrow 2)]- β -D-galactopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxo-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester, monoammonium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 865529-65-3 CAPLUS


CN Octadecanoic acid, (1R)-1-[17-[[O-2-(acetylamino)-2-deoxy- α -D-galactopyranosyl-(1 \rightarrow 3)-O-[6-deoxy- α -L-galactopyranosyl-(1 \rightarrow 2)]- β -D-galactopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxo-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 865529-66-4 CAPLUS

CN Octadecanoic acid, (1R)-1-[17-[[O-2-(acetylamino)-2-deoxy- α -D-galactopyranosyl-(1 \rightarrow 3)-O-[6-deoxy- α -L-galactopyranosyl-(1 \rightarrow 2)]- β -D-galactopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxo-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Na




RN 865529-67-5 CAPLUS

CN Octadecanoic acid, (1R)-1-[17-[[O-2-(acetylamino)-2-deoxy- α -D-galactopyranosyl-(1 \rightarrow 3)-O-[6-deoxy- α -L-galactopyranosyl-(1 \rightarrow 2)]- β -D-galactopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxo-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester, monopotassium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.





● K



RN 865529-68-6 CAPLUS

CN Octadecanoic acid, (1R)-1-[17-[[O-2-(acetylamino)-2-deoxy- α -D-galactopyranosyl-(1 \rightarrow 3)-O-[6-deoxy- α -L-galactopyranosyl-(1 \rightarrow 2)]- β -D-galactopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxo-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester, monoammonium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 865529-69-7 CAPLUS


CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[O-6-deoxy- α -L-galactopyranosyl-(1 \rightarrow 2)-O-[α -D-galactopyranosyl-(1 \rightarrow 3)]- β -D-galactopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxo-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





PAGE 1-B



RN 865529-70-0 CAPLUS

CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[O-6-deoxy- α -L-galactopyranosyl-(1 \rightarrow 2)-O-[α -D-galactopyranosyl-(1 \rightarrow 3)]- β -D-galactopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxo-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester, monosodium salt (9CI)
(CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.




RN 865529-71-1 CAPLUS

CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[O-6-deoxy- α -L-galactopyranosyl-(1 \rightarrow 2)-O-[α -D-galactopyranosyl-(1 \rightarrow 3)]- β -D-galactopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxa-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester, monopotassium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.





● K



RN 865529-72-2 CAPLUS

CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[O-6-deoxy- α -L-galactopyranosyl-(1 \rightarrow 2)-O-[α -D-galactopyranosyl-(1 \rightarrow 3)]- β -D-galactopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxa-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester, monoammonium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 865529-73-3 CAPLUS


CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[O-6-deoxy- α -L-galactopyranosyl-(1 \rightarrow 2)-O- β -D-galactopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxo-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 865529-74-4 CAPLUS

CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[O-6-deoxy- α -L-galactopyranosyl-(1 \rightarrow 2)-O- β -D-galactopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxo-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.





● Na



RN 865529-75-5 CAPLUS

CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[O-6-deoxy- α -L-galactopyranosyl-(1 \rightarrow 2)-O- β -D-galactopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxo-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester, monoammonium salt (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.




RN 865529-76-6 CAPLUS

CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[O-6-deoxy- α -L-galactopyranosyl-(1 \rightarrow 2)-O- β -D-galactopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxo-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester, monopotassium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



● K




RN 865529-77-7 CAPLUS


CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[2-O-(6-deoxy- α -L-galactopyranosyl)- β -D-galactopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxo-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





PAGE 1-B



RN 865529-78-8 CAPLUS

CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[2-O-(6-deoxy-α-L-galactopyranosyl)-β-D-galactopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxo-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 865529-79-9 CAPLUS


CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[2-O-(6-deoxy- α -L-galactopyranosyl)- β -D-galactopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxo-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester, monopotassium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



● K





RN 865529-80-2 CAPLUS

CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[2-O-(6-deoxy- α -L-galactopyranosyl)- β -D-galactopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxo-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester, monoammonium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.




RN 865529-81-3 CAPLUS

CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-(β-D-galactopyranosyloxy)-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxo-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.







RN 865529-82-4 CAPLUS

CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-(β -D-galactopyranosyloxy)-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxo-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




● Na




RN 865529-83-5 CAPLUS

CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-(β -D-galactopyranosyloxy)-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxo-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester, monopotassium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




● K




RN 865529-84-6 CAPLUS

CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-(β -D-galactopyranosyloxy)-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxo-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester, monoammonium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




● NH₃





RN 865529-85-7 CAPLUS

CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[O-6-deoxy- α -L-galactopyranosyl-(1 \rightarrow 2)-O- β -D-galactopyranosyl-(1 \rightarrow 3)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 3)-O- β -D-galactopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxo-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.








RN 865529-85-7 CAPLUS

CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[O-6-deoxy- α -L-galactopyranosyl-(1 \rightarrow 2)-O- β -D-galactopyranosyl-(1 \rightarrow 3)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 3)-O- β -D-galactopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxa-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 865529-86-8 CAPLUS

CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[O-6-deoxy- α -L-galactopyranosyl-(1 \rightarrow 2)-O- β -D-galactopyranosyl-(1 \rightarrow 3)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 3)-O- β -D-


galactopyranosyl-(1→4)-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxo-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester, monosodium salt (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B







RN 865529-87-9 CAPLUS

CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[O-6-deoxy- α -L-galactopyranosyl-(1 \rightarrow 2)-O- β -D-galactopyranosyl-(1 \rightarrow 3)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 3)-O- β -D-galactopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxo-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester, monopotassium salt (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



PAGE 1-B



PAGE 2-A




● K

RN 865529-88-0 CAPLUS


CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[O-6-deoxy- α -L-galactopyranosyl-(1 \rightarrow 2)-O- β -D-galactopyranosyl-(1 \rightarrow 3)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 3)-O- β -D-galactopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxo-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester, monoammonium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


PAGE 1-A



PAGE 1-B



PAGE 2-A




● NH₃


RN 865529-89-1 CAPLUS
 CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[O-6-deoxy- α -L-galactopyranosyl-(1 \rightarrow 2)-O- β -D-galactopyranosyl-(1 \rightarrow 3)-O-[6-deoxy- α -L-galactopyranosyl-(1 \rightarrow 4)]-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxo-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B







RN 865529-89-1 CAPLUS

CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[O-6-deoxy- α -L-galactopyranosyl-(1 \rightarrow 2)-O- β -D-galactopyranosyl-(1 \rightarrow 3)-O-[6-deoxy- α -L-galactopyranosyl-(1 \rightarrow 4)]-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxo-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.







RN 865529-90-4 CAPLUS

CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[O-6-deoxy- α -L-galactopyranosyl-(1 \rightarrow 2)-O- β -D-galactopyranosyl-(1 \rightarrow 3)-O-[6-deoxy- α -L-galactopyranosyl-(1 \rightarrow 4)]-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxo-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester, monosodium salt (9CI)
(CA INDEX NAME)



Absolute stereochemistry.
Double bond geometry as shown.





RN 865529-91-5 CAPLUS
 CN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[O-6-deoxy- α -L-galactopyranosyl-(1 \rightarrow 2)-O- β -D-galactopyranosyl-(1 \rightarrow 3)-O-[6-deoxy- α -L-galactopyranosyl-(1 \rightarrow 4)]-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxo-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester, monopotassium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.







RN 865529-92-6 CAPLUS

CN Phosphoric acid, mono[2-[[6-[[3-[[O-6-deoxy- α -L-galactopyranosyl-(1 \rightarrow 2)-O- β -D-galactopyranosyl-(1 \rightarrow 3)-O-[6-deoxy- α -L-galactopyranosyl-(1 \rightarrow 4)]-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl]oxy]propyl]amino]-1,6-dioxohexyl]amino]ethyl] mono[(2R)-2,3-bis[[[(9Z)-1-oxo-9-octadecenyl]oxy]propyl] ester, monoammonium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.





OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> e bovin nicolai/au

E1	8	BOVIN N I/AU
E2	181	BOVIN N V/AU
E3	45 -->	BOVIN NICOLAI/AU
E4	1	BOVIN NICOLAI N/AU
E5	83	BOVIN NICOLAI V/AU
E6	2	BOVIN NICOLAI VLADIMIROVICH/AU
E7	4	BOVIN NIKOLAI/AU
E8	6	BOVIN NIKOLAI V/AU
E9	1	BOVIN NIKOLAI VLADIMIROVICH/AU

E10	3	BOVIN NIKOLAJ V/AU
E11	1	BOVIN NIKOLAY/AU
E12	1	BOVIN NIKOLAY V/AU

=> s e1-e9

THE ESTIMATED SEARCH COST FOR FILE 'CAPLUS' IS 20.79 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y

	8	"BOVIN N I"/AU
	181	"BOVIN N V"/AU
	45	"BOVIN NICOLAI"/AU
	1	"BOVIN NICOLAI N"/AU
	83	"BOVIN NICOLAI V"/AU
	2	"BOVIN NICOLAI VLADIMIROVICH"/AU
	4	"BOVIN NIKOLAI"/AU
	6	"BOVIN NIKOLAI V"/AU
	1	"BOVIN NIKOLAI VLADIMIROVICH"/AU
L14	331	("BOVIN N I"/AU OR "BOVIN N V"/AU OR "BOVIN NICOLAI"/AU OR "BOVIN NICOLAI N"/AU OR "BOVIN NICOLAI V"/AU OR "BOVIN NICOLAI VLADIMIROVICH"/AU OR "BOVIN NIKOLAI"/AU OR "BOVIN NIKOLAI V"/AU OR "BOVIN NIKOLAI VLADIMIROVICH"/AU)

=> e gilliver lissa/au

E1	4	GILLIVER K/AU
E2	1	GILLIVER L G/AU
E3	1	--> GILLIVER LISSA/AU
E4	3	GILLIVER LISSA GWYNETH/AU
E5	1	GILLIVER LOUISE/AU
E6	1	GILLIVER MERV/AU
E7	1	GILLIVER MOIRA A/AU
E8	1	GILLIVER P J/AU
E9	1	GILLIVER PETER J/AU
E10	2	GILLIVER S C/AU
E11	1	GILLIVER S F/AU
E12	5	GILLIVER STEPHEN C/AU

=> s e3-e4

	1	"GILLIVER LISSA"/AU
	3	"GILLIVER LISSA GWYNETH"/AU
L15	4	("GILLIVER LISSA"/AU OR "GILLIVER LISSA GWYNETH"/AU)

=> e henry stephen/au

E1	1	HENRY STANLEY MICHELLE JENNEE/AU
E2	2	HENRY STEPHANIE/AU
E3	17	--> HENRY STEPHEN/AU
E4	1	HENRY STEPHEN F/AU
E5	3	HENRY STEPHEN G/AU
E6	6	HENRY STEPHEN M/AU
E7	4	HENRY STEPHEN MICHAEL/AU
E8	4	HENRY STEPHEN MICHEAL/AU
E9	4	HENRY STEPHEN P/AU
E10	1	HENRY STEPHEN PHILIP/AU
E11	5	HENRY STEVE/AU
E12	3	HENRY STEVEN/AU

=> s e3-e10

17	"HENRY STEPHEN"/AU
1	"HENRY STEPHEN F"/AU
3	"HENRY STEPHEN G"/AU
6	"HENRY STEPHEN M"/AU

```

4 "HENRY STEPHEN MICHAEL"/AU
4 "HENRY STEPHEN MICHEAL"/AU
4 "HENRY STEPHEN P"/AU
1 "HENRY STEPHEN PHILIP"/AU
L16 40 ("HENRY STEPHEN"/AU OR "HENRY STEPHEN F"/AU OR "HENRY STEPHEN
      G"/AU OR "HENRY STEPHEN M"/AU OR "HENRY STEPHEN MICHAEL"/AU OR
      "HENRY STEPHEN MICHEAL"/AU OR "HENRY STEPHEN P"/AU OR "HENRY
      STEPHEN PHILIP"/AU)

=> e korchagina elena/au
E1      6      KORCHAGINA E Y/AU
E2      14     KORCHAGINA E YU/AU
E3      6  --> KORCHAGINA ELENA/AU
E4      14     KORCHAGINA ELENA Y/AU
E5      3      KORCHAGINA ELENA YU/AU
E6      2      KORCHAGINA ELENA YURIEVNA/AU
E7      12     KORCHAGINA G A/AU
E8      5      KORCHAGINA G K/AU
E9      5      KORCHAGINA G P/AU
E10     8      KORCHAGINA G T/AU
E11     2      KORCHAGINA G V/AU
E12     1      KORCHAGINA GALINA T/AU

=> s e1-e6
        6 "KORCHAGINA E Y"/AU
        14 "KORCHAGINA E YU"/AU
        6 "KORCHAGINA ELENA"/AU
        14 "KORCHAGINA ELENA Y"/AU
        3 "KORCHAGINA ELENA YU"/AU
        2 "KORCHAGINA ELENA YURIEVNA"/AU
L17 45 ("KORCHAGINA E Y"/AU OR "KORCHAGINA E YU"/AU OR "KORCHAGINA ELEN
      A"/AU OR "KORCHAGINA ELENA Y"/AU OR "KORCHAGINA ELENA YU"/AU OR
      "KORCHAGINA ELENA YURIEVNA"/AU)

=> l17 or l16 or l15 or l14
L18      371 L17 OR L16 OR L15 OR L14

=> l18 and (membrane or lipid)
      875821 MEMBRANE
      369106 MEMBRANES
      975646 MEMBRANE
            (MEMBRANE OR MEMBRANES)
      345394 LIPID
      238549 LIPIDS
      418675 LIPID
            (LIPID OR LIPIDS)
L19      41 L18 AND (MEMBRANE OR LIPID)

=> l19 and ?phospholipid?
      148097 ?PHOSPHOLIPID?
L20      6 L19 AND ?PHOSPHOLIPID?

=> d l20 1-6 ibib abs

```

L20 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:456160 CAPLUS

DOCUMENT NUMBER: 150:417193

TITLE: Functional lipid constructs and method of
detecting reactive antibody and method of immobilizing

cells or multicellular structures

INVENTOR(S): Bovin, Nicolai; Henry, Stephen Micheal; Rodinov, Igor; Weinberg, Cristina-Simona

PATENT ASSIGNEE(S): Russia

SOURCE: PCT Int. Appl., 138pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009048343	A1	20090416	WO 2008-NZ266	20081013
<p>W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW</p> <p>RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM</p>				
PRIORITY APPLN. INFO.:			NZ 2007-562475	A 20071012
			NZ 2008-569024	A 20080606
			NZ 2008-569059	A 20080610
			NZ 2008-569912	A 20080707
			NZ 2008-569964	A 20080718

OTHER SOURCE(S): MARPAT 150:417193

AB The invention relates to methods for effecting qual. and quant. changes in the functional moieties expressed at the surface of cells and multi-cellular structures, and functional lipid constructs for use in such methods. In particular, the invention relates to functional lipid constructs and their use in diagnostic and therapeutic applications, including serodiagnosis, where the functional moiety is a carbohydrate, peptide, chemical reactive group, conjugator or fluorophore.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:335442 CAPLUS

DOCUMENT NUMBER: 150:350139

TITLE: Peptide-lipid constructs and their use in diagnostic and therapeutic applications

INVENTOR(S): Weinberg, Cristina-Simona; Bovin, Nicolai; Henry, Stephen Micheal

PATENT ASSIGNEE(S): N. Z.

SOURCE: PCT Int. Appl., 80pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009035347	A1	20090319	WO 2008-NZ239	20080911

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: NZ 2007-561381 A 20070911
 NZ 2007-562475 A 20071012
 NZ 2008-569023 A 20080606

OTHER SOURCE(S): MARPAT 150:350139

AB Peptide-lipid constructs of the structure L-S-F are disclosed, where F is a peptide, S is a spacer covalently linking F to L via an oligomer of ethylene glycol, and L is a diacyl- or dialkyl-glycerolipid (including glycerophospholipids). The spacer ideally has 6 to 14 ethylene glycol repeats, corresponding to PEG with a mol. weight of approx. 250 to 600. Also disclosed is a method of detecting reactive antibodies in serum by contacting serum with cells modified to incorporate a peptide-lipid construct, where the peptide is an epitope of the antibody, and determining the degree of agglutination of the cells. In one example, the peptides comprise determinants of the Miltenberger variants of the MNSs system.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:1341454 CAPLUS

DOCUMENT NUMBER: 149:534508

TITLE: Preparation of carbohydrate-lipid analogs and their use in preventing or treating viral infection

INVENTOR(S): Henry, Stephen Micheal

PATENT ASSIGNEE(S): Kode Biotech Ltd., N. Z.

SOURCE: PCT Int. Appl., 87pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008133534	A2	20081106	WO 2008-NZ95	20080428
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

AU 2008244737	A1	20081106	AU 2008-244737	20080428
CA 2685269	A1	20081106	CA 2008-2685269	20080428
PRIORITY APPLN. INFO.:			NZ 2007-554853	A 20070427
			NZ 2007-556736	A 20070724
			NZ 2008-567754	A 20080424
			WO 2008-NZ95	W 20080428

OTHER SOURCE(S): MARPAT 149:534508

AB Carbohydrate-lipid analogs are prepared for their use as mimics of ligands for receptors expressed by a virus. In particular, the invention relates to the use of selected carbohydrate-lipid constructs in methods of inhibiting virus infection and/or promoting clearance of virus from infected subjects. Carbohydrate-lipid constructs selected for use in these methods where the virus is Human Immunodeficiency Virus (HIV) are provided.

L20 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:322099 CAPLUS
DOCUMENT NUMBER: 148:326200
TITLE: Fluorescent cell markers containing fluorophore and diacyl lipid
INVENTOR(S): Korchagina, Elena; Bovin, Nicolai; Henry, Stephen
PATENT ASSIGNEE(S): Russia
SOURCE: PCT Int. Appl., 35pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2008030115	A2	20080313	WO 2007-NZ256	20070906
WO 2008030115	A3	20080828		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
AU 2007293770	A1	20080313	AU 2007-293770	20070906
CA 2662624	A1	20080313	CA 2007-2662624	20070906
EP 2069460	A2	20090617	EP 2007-834859	20070906
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR				
PRIORITY APPLN. INFO.:			NZ 2006-549742	A 20060906
			NZ 2006-549740	A 20060907
			WO 2007-NZ256	W 20070906

OTHER SOURCE(S): MARPAT 148:326200

AB The preparation and use of fluorescent cell markers of the structure F-S1-S2-L is described where F is a fluorophore, S1-S2 is a spacer linking F to L, and L is a diacyl lipid.

L20 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2005:1042259 CAPLUS
 DOCUMENT NUMBER: 143:339681
 TITLE: Synthetic membrane anchors
 INVENTOR(S): Bovin, Nicolai; Gilliver, Lissa; Henry, Stephen; Korchagina, Elena
 PATENT ASSIGNEE(S): Kiwi Ingenuity Limited, N. Z.
 SOURCE: PCT Int. Appl., 109 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005090368	A1	20050929	WO 2005-NZ52	20050322
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2005223715	A1	20050929	AU 2005-223715	20050322
CA 2560781	A1	20050929	CA 2005-2560781	20050322
EP 1735323	A1	20061227	EP 2005-722123	20050322
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR			
CN 1938325	A	20070328	CN 2005-80009170	20050322
JP 2007530532	T	20071101	JP 2007-504907	20050322
IN 2006DN06089	A	20070831	IN 2006-DN6089	20061018
US 20070197466	A1	20070823	US 2007-593829	20070112
PRIORITY APPLN. INFO.:			NZ 2004-531866	A 20040322
			NZ 2005-537941	A 20050128
			WO 2005-NZ52	W 20050322

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 143:339681

AB The invention relates to synthetic mols. such as modified glycolipids that spontaneously and stably incorporate into lipid by-layers, including cell membranes. Particularly, although not exclusively, the invention relates to the use of these mols. as synthetic membrane anchors or synthetic mol. constructs to effect qual. and quant. changes in the expression of cell surface antigens. Being able to effect qual. and/or quant. changes in the surface antigens expressed by a cell has diagnostic and therapeutic value. In a first aspect the invention consists in a mol. of the structure R-S2-L for use as a synthetic membrane anchor or in the preparation of synthetic mol. constructs where: R is a chemical reactive functional group such as bis(N-hydroxysuccinimidyl), bis(4-nitrophenyl), bis(pentafluorophenyl), and bis(pentachlorophenyl); S2 is a spacer linking R to L such as -CO(CH2)3CO-, -CO(CH2)4CO-(adipate (Ad)), and -CO(CH2)5CO-; and L is a lipid selected from the group consisting of diacyl- and dialkylglycerolipids, including glycerophospholipids, and sphingosine derived diacyl- and dialkylipids, including ceramide. In a second aspect, the invention consists in a synthetic mol. construct of the structure F-S1-S2-L where: F is an antigen selected from the group

consisting of carbohydrates, proteins, lipids, lectins, avidins and biotin; S1-S2 is a spacer linking F to L; and L is a lipid selected from the group consisting of diacyl- and dialkylglycerolipids, including glycerophospholipids, and sphingosine derived diacyl- and dialkylipids, including ceramide.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:837267 CAPLUS

DOCUMENT NUMBER: 139:319673

TITLE: Glycolipid-inserted embryo for the preparation of an embryo modified to enhance the implantation into the endometrium

INVENTOR(S): Blake, Deborah Adella; Carter, Nicola Lewell;

Henry, Stephen Michael

PATENT ASSIGNEE(S): Kiwi Ingenuity Limited, N. Z.

SOURCE: PCT Int. Appl., 75 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003087346	A1	20031023	WO 2003-NZ59	20030407
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
NZ 518163	A	20050429	NZ 2002-518163	20020405
CA 2481256	A1	20031023	CA 2003-2481256	20030407
AU 2003222519	A1	20031027	AU 2003-222519	20030407
EP 1497411	A1	20050119	EP 2003-717799	20030407
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 20060089523	A1	20060427	US 2005-510377	20051107
PRIORITY APPLN. INFO.:			NZ 2002-518163	A 20020405
			WO 2003-NZ59	W 20030407

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention relates to constructs and methods used to enhance the attachment and implantation of an embryo. It is shown that modified glycolipids and glycolipid-attachment mol. constructs can be used to modify embryos, or localized to target tissues, to enhance interaction between the embryo and the target tissue, (typically the endometrium). The invention may advantageously be used to enhance implantation of embryos in the uterus, for example, in IVF treatments.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

